Both prohibit a pharmaceutical company from direct to consumer advertising which includes issuing public press statements about our prescription medicines. We are able to issue public statements to advise registration of a new medicine, a reimbursement notice of a new medicine or any general corporate news not related to our medicines. For any specific issues please contact the Communications Manager.
24/02/19: Keytruda ® (pembrolizumab) PBS listed for advanced form of bladder cancer 1
Australians battling a form of cancer which has seen no improvement in survival rates in the past 30 years 2 may now be eligible for Pharmaceutical Benefits Scheme subsidised access to a medicine that activates the body’s immune system to detect and attack tumour cells.1,3 More
28/10/18: Government subsidy for KEYTRUDA ® (pembrolizumab) to help fight Australia’s leading cause of cancer death 1,2
MSD is committed to providing access to KEYTRUDA for eligible lung cancer patients. Today marks a crucial first step in providing reimbursed immunotherapy as a first-line treatment for thousands of eligible Australians battling a type of advanced. More
17/08/18: Government today poised to consider innovative access solutions for cancer treatments
MSD Australia welcomes the Pharmaceutical Benefits Advisory Committee’s (PBAC) consideration of proposals to subsidise immuno-oncology (IO) medicines across multiple tumour types for Australian cancer patients at a Special Meeting being held today. More
29/06/18: Government urged to fund potentially lifesaving immunotherapy cancer medicines
MSD Australia today acknowledged the work being undertaken by Federal Health Minister, The Hon Greg Hunt MP to drive increased access to immuno-oncology (IO) medicines through a multi-cancer approach and urged the government to commit appropriate funds. More
21/02/18: Third year running - MSD recognised as Employer of Choice for Gender Equality
Australia’s Workplace Gender Equality Agency (WGEA) has today recognised MSD, a leading biopharmaceutical company, as an Employer of Choice for Gender Equality (EOCGE). More
29/08/17: Lung cancer patients die sooner in Australia than Taiwan – new analysis
Australians with advanced lung cancer are unlikely to survive longer than two years after they commence treatment, according to new research which has highlighted the limitations of chemotherapy as a front-line defence against the nation’s leading cancer killer more
10/05/2017: Federal Budget: MSD welcomes investment fund for new medicines
MSD today welcomed the Treasurer’s announcement that a new fund will be created to invest in innovative new medicines more
30/01/2017: Report shows more work is needed in fight against cardiovascular disease
MSD today welcomed many of the recommendations proposed in a report made public by the Department of Health as part of a Post-market Review into MSD’s cholesterol lowering medicine Ezetimibe (the product). more
25/01/2017: ‘Head in the sand’ attitude may put hearts at risk – new research
New research reveals that ageing Australians consider themselves thinner, fitter and healthier than they actually are, placing many in the firing line for life-threatening heart attack and stroke. more
18/01/2017: MSD welcomes new Minister for Health
MSD today welcomed the Prime Minister’s announcement that the Hon. Greg Hunt will be taking over as the Minister for Health, and Minister for Sport. more
05/11/2015: MSD awarded Employer of Choice for Gender Equality
The Workplace Gender Equality Agency (WGEA) has today awarded MSD the Employer of Choice for Gender Equality citation for 2015. more
24/06/2015: MSD and One Disease Announce $1.2 Million to Improve Indigenous Life Expectancy
The goal of closing the life-expectancy gap between Indigenous and non-Indigenous Australians is now one-step closer thanks to a $1.2 million donation to the cause today. MSD in Australia, a subsidiary of Merck & Co. Inc. donated $600,000 to not-for-profit organisation One Disease, which is also being matched dollar-for-dollar by an unnamed benefactor... more